Henry Schein (NASDAQ:HSIC) Price Target Raised to $76.00

Henry Schein (NASDAQ:HSIC) had its price target increased by Wells Fargo & Company from $70.00 to $76.00 in a report released on Wednesday,Benzinga reports. They currently have an equal weight rating on the stock.

Several other analysts have also issued reports on the company. Robert W. Baird reaffirmed a “neutral” rating and issued a $72.00 target price (down previously from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. Baird R W cut shares of Henry Schein from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 14th. Stifel Nicolaus restated a “hold” rating and set a $75.00 price target (down from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Barrington Research restated an “outperform” rating and set a $78.00 target price on shares of Henry Schein in a report on Wednesday, October 22nd. Finally, Leerink Partners set a $75.00 target price on shares of Henry Schein in a report on Monday, July 14th. Five research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $76.08.

Henry Schein Price Performance

Shares of NASDAQ:HSIC traded up $1.84 on Wednesday, hitting $71.90. The company’s stock had a trading volume of 1,452,270 shares, compared to its average volume of 1,725,097. The company has a market capitalization of $8.72 billion, a PE ratio of 23.19, a PEG ratio of 2.06 and a beta of 0.84. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The company has a 50-day simple moving average of $66.30 and a 200 day simple moving average of $68.71. Henry Schein has a 1 year low of $60.56 and a 1 year high of $82.49.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.34 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Sell-side analysts forecast that Henry Schein will post 4.74 EPS for the current fiscal year.

Institutional Trading of Henry Schein

Hedge funds and other institutional investors have recently modified their holdings of the business. CYBER HORNET ETFs LLC purchased a new position in Henry Schein during the 2nd quarter valued at about $25,000. MUFG Securities EMEA plc bought a new position in shares of Henry Schein during the second quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Henry Schein in the 2nd quarter worth approximately $43,000. Steph & Co. purchased a new position in Henry Schein during the second quarter valued at $44,000. Finally, CX Institutional grew its stake in shares of Henry Schein by 107.3% in the second quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after acquiring an additional 337 shares during the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.